Bristol-Myers Squibb (NY:BMY)

61.55 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

95 96 Next >

Which S&P500 stocks are moving on Friday? ↗

December 12, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

December 12, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at Guggenheim upgraded the company's stock from "Neutral" to "Buy" and set a...

Via StockStory

Topics Artificial Intelligence Supply Chain

Top S&P500 movers in Friday's session ↗

December 12, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.

Via Chartmill

The Best Turnaround Stock to Invest $1,000 in Right Now ↗

December 12, 2025

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.

Via The Motley Fool

Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles

December 12, 2025

As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

December 11, 2025

From Bristol Myers Squibb

Via Business Wire

December 10, 2025

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

Bristol Myers Squibb Announces Dividend Increase

December 10, 2025

From Bristol Myers Squibb

Via Business Wire

2 Pharmaceutical Stocks to Buy at a Discount ↗

December 10, 2025

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

Via The Motley Fool

Topics Intellectual Property

1 Large-Cap Stock on Our Buy List and 2 We Turn Down

December 08, 2025

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Via StockStory

Do These 3 Healthcare Stocks Need a Checkup? ↗

December 05, 2025

These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 04, 2025

From Bristol Myers Squibb

Via Business Wire

3 Stocks Under $50 We’re Skeptical Of

December 03, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

Which S&P500 stocks are moving on Wednesday? ↗

December 03, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

December 03, 2025

Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Bristol Myers Stock Jumps As Wall Street Backs Added Enrollment In Alzheimer’s Trial — Retail Calls It ‘Worth A Play’ ↗

December 03, 2025

Bristol Myers’ ADEPT-2 update drew support from JPMorgan and William Blair following the decision to continue the study with added enrollment.

Via Stocktwits

These S&P500 stocks are moving in today's pre-market session ↗

December 03, 2025

Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

December 03, 2025

From Bristol Myers Squibb

Via Business Wire

Amazon Unleashes AI Frontier Agents: A New Era of Autonomous Digital Workers

December 02, 2025

Amazon (NASDAQ: AMZN) has unveiled a groundbreaking class of AI agents, dubbed "frontier agents," capable of operating autonomously for extended periods—even days—without constant human intervention....

Via TokenRing AI

Topics Artificial Intelligence Economy

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

Via Investor Brand Network

Topics Government

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

From BioMedWire

Via GlobeNewswire

Bristol-Myers Squibb Co (NYSE:BMY) Presents a Compelling Value Investment Case ↗

December 02, 2025

Bristol-Myers Squibb (BMY) presents a value investment case, trading at a deep discount with strong earnings power and a high dividend amid near-term challenges.

Via Chartmill

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

December 01, 2025

From Bristol Myers Squibb

Via Business Wire

2 Undervalued, High-Quality Companies to Buy Now and Hold Forever ↗

November 30, 2025

If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive.

Via The Motley Fool

Topics Intellectual Property

2 Top Dividend Stocks to Buy and Hold ↗

November 30, 2025

Patience will be rewarded for those who stick with these two healthcare stocks.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend? ↗

November 29, 2025

The pharma stock yields more than 4x the S&P 500 average.

Via The Motley Fool

Topics Intellectual Property Stocks

Bristol-Myers (BMY) Earnings Call Transcript ↗

November 27, 2025

Bristol-Myers (BMY) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Offers a Compelling Mix of High Yield and Financial Strength for Dividend Investors ↗

November 27, 2025

Bristol-Myers Squibb (BMY) offers a strong 5.4% dividend yield, backed by a history of reliable payments, robust profitability, and a sound financial position for income investors.

Via Chartmill

Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference

November 26, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

November 24, 2025

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

95 96 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.